Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 8:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 77 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Omeprazole 20mg BID Clear all
Completed Phase 2 Interventional Results available

Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus

NCT00474903
View directory record Official record
Conditions
Barrett Esophagus, Esophageal Cancer
Interventions
acetylsalicylic acid, esomeprazole magnesium, placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 2, 2026, 8:09 AM EDT
Completed Phase 2 Interventional Results available

Effect of Proton Pump Inhibitors on CF Pulmonary Exacerbations

NCT01983774
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Esomeprazole, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Oct 2, 2026, 8:09 AM EDT
Completed Phase 3 Interventional Results available

Study of Acid Reflux in Asthma

NCT00069823
View directory record Official record
Conditions
Asthma, Lung Diseases, Lung Diseases, Obstructive
Interventions
Esomeprazole, Placebo proton pump inhibitor
Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
20
States / cities
Birmingham, Alabama • San Diego, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2012 · Synced Oct 2, 2026, 8:09 AM EDT
Terminated Phase 4 Interventional Results available

PROUD Study - Preventing Opioid Use Disorders

NCT04766996
View directory record Official record
Conditions
Anesthesia, Opioid Use
Interventions
Guided mindfulness exercises, Self-administered aromatherapy, Baby aspirin, Tylenol/Acetaminophen, Pregabalin, Prednisone, Meloxicam, Prilosec, Tramadol, Voltaren, Zofran, Pepcid, Reglan, Versed, Lidocaine, Propofol, Ancef, Tranexamic Acid (TXA), Decadron, Bupivacaine hydrochloride, Toradol
Behavioral · Other · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 2, 2026, 8:09 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)

NCT00978016
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
arbaclofen placarbil-Cohort 1, Placebo-Cohort 5, arbaclofen placarbil-Cohort 2, arbaclofen placarbil-Cohort 3, arbaclofen placarbil-Cohort 4, PPI
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
62
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 2, 2026, 8:09 AM EDT
Completed Phase 2 Interventional

Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis

NCT00123656
View directory record Official record
Conditions
Esophagitis
Interventions
esomeprazole, fluticasone
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 16, 2008 · Synced Oct 2, 2026, 8:09 AM EDT
Completed Phase 1 Interventional

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

NCT01042704
View directory record Official record
Conditions
Myeloma
Interventions
Bendamustine, Lenalidomide, Dexamethasone, Aspirin, Prophylaxis, Antibiotic, Biweekly Follow Up, Cyclical Follow Up, Restaging, Post-Treatment Follow Up
Drug · Other
Lead sponsor
Robert Redner, MD
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
22
States / cities
Detroit, Michigan • Steubenville, Ohio • Beaver, Pennsylvania + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 2, 2026, 8:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Gastric pH Changes Induced by Ascorbic Acid Tablets

NCT04199624
View directory record Official record
Conditions
Hypochlorhydria
Interventions
Omeprazole 20mg, Vitamin C
Drug · Dietary Supplement
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 2, 2026, 8:09 AM EDT
Withdrawn Not applicable Interventional

Confocal Endomicroscopy for Non-Erosive Reflux Disease (CE NERD)

NCT02039869
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Non Erosive Reflux Disease, Dyspepsia
Interventions
Confocal endomicroscopy, Proton pump inhibitor, Sucralfate
Device · Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Kenner, Louisiana • Charleston, South Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Oct 2, 2026, 8:09 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Standard Triple Therapy vs Sequential Therapy in Treatment of H Pylori Infection

NCT01723059
View directory record Official record
Conditions
Helicobacter Infection
Interventions
Standard Triple Therapy, Sequential Therapy
Drug
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years to 85 Years
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2012 · Synced Oct 2, 2026, 8:09 AM EDT
Completed Phase 2 Interventional Results available

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

NCT00001337
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma, Anaplastic Large-Cell Lymphoma, Gray Zone Lymphoma
Interventions
Etoposide, Rituximab, Prednisone, Cyclophosphamide, Vincristine, Doxorubicin, MRI, CT, Biopsy, PET scan, Laparotomy, Ondansetron, Prochlorperazine, Omeprazole, Docusate Sodium + Sennosides, Lactulose
Drug · Biological · Diagnostic Test + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2024
U.S. locations
5
States / cities
Fort Lauderdale, Florida • Baltimore, Maryland • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 2, 2026, 8:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Plasm Gastrin Concentrations in Response to Nexium Administration in Healthy Volunteers

NCT01135472
View directory record Official record
Conditions
Healthy
Interventions
Esomeprazole Magnesium
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Oct 2, 2026, 8:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects

NCT03302845
View directory record Official record
Conditions
Drug-drug Interaction
Interventions
Omeprazole 40 MG, Famotidine 40 mg, Telotristat ethyl 250 mg
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Oct 2, 2026, 8:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of Clemizole (EPX-100) in Healthy Participants

NCT07824193
View directory record Official record
Conditions
Drug Drug Interaction
Interventions
EPX-100, Itraconazole, Phenytoin, Omeprazole, Midazolam, Bupropion
Drug
Lead sponsor
Epygenix
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 2, 2026, 8:09 AM EDT
Completed Phase 4 Interventional Results available

Placebo In Chronic Back Pain (Phase 2)

NCT02986334
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Naproxen, Omeprazole, Placebo
Drug
Lead sponsor
Apkar Apkarian
Other
Eligibility
18 Years to 75 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Oct 2, 2026, 8:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple-Dose Pharmacokinetics Study of Three Gefapixant (AF-219/MK-7264) Formulations

NCT02790840
View directory record Official record
Conditions
Healthy
Interventions
Omeprazole, Gefapixant
Drug
Lead sponsor
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 2, 2026, 8:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics

NCT01841489
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Treatment A, Treatment B, Treatment C, Treatment D, Treatment E, Treatment F, Treatment G, Treatment H, Treatment I, Treatment J
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 7, 2014 · Synced Oct 2, 2026, 8:09 AM EDT
Completed Phase 4 Interventional Results available

Placebo In Chronic Back Pain - Double-Blind Randomized Control Trial

NCT02013427
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Naproxen, Placebo, Omeprazole
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 2, 2026, 8:09 AM EDT
Completed Phase 2 Interventional Results available

Dermaprazole Cream for Radiation Dermatitis in Head and Neck Cancer

NCT04865731
View directory record Official record
Conditions
Cancer of the Head and Neck
Interventions
Dermaprazole, Aquaphor
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 2, 2026, 8:09 AM EDT
Completed Phase 1 Interventional Results available

Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients

NCT03028103
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma, Mantle Cell Lymphoma, Advanced Solid Tumor, Marginal Zone Lymphoma
Interventions
Tazemetostat, Fluconazole, Omeprazole, Repaglinide
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Tucson, Arizona • Tampa, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 2, 2026, 8:09 AM EDT
Completed Not applicable Interventional Results available

Fluticasone Versus Esomeprazole to Treat Eosinophilic Esophagitis

NCT00895817
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Swallowed fluticasone, Esomeprazole
Drug
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2013 · Synced Oct 2, 2026, 8:09 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib

NCT01844583
View directory record Official record
Conditions
Solid Tumors, Lymphoma
Interventions
Alisertib, Esomeprazole, Rifampin
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Sarasota, Florida • St Louis, Missouri • Oklahoma City, Oklahoma + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Oct 2, 2026, 8:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial to Evaluate MK-4208/TERN-701 in Healthy Adult Participants (MK-4208-001/TERN701-1014)

NCT07838987
View directory record Official record
Conditions
Healthy
Interventions
TERN-701, Rabeprazole, Midazolam, Digoxin, Pravastatin, Montelukast, Omeprazole, Itraconazole, Warfarin, Rosuvastatin, Bosentan, Quinidine
Drug
Lead sponsor
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 65 Years
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Millcreek, Utah
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 2, 2026, 8:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple-Dose Pharmacokinetics Study of Two Gefapixant (AF-219/MK-7264) Formulations

NCT02492776
View directory record Official record
Conditions
Healthy
Interventions
Omeprazole, Gefapixant
Drug
Lead sponsor
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 2, 2026, 8:09 AM EDT